25
Participants
Start Date
February 18, 2022
Primary Completion Date
October 16, 2023
Study Completion Date
October 16, 2023
HIVIS DNA/MVA-CMDR
HIVIS DNA IM by needle-free injection at weeks 0 and 4 followed by intramuscular (IM) needle injection of 1 X 108 IU/mL (1ml) MVA-CMDR at weeks 24 and 36 in the same arm as HIVIS DNA.
HIVIS DNA + Cervarix and MVA-CMDR
Cervarix IM by needle injection followed by 1500 micrograms (0.5ml) per injection of HIVIS DNA IM by a needle-free injection device in the skin above (proximal to) the Cervarix injection (within 1.5 cm). They will receive 1 X 108 IU/mL (1ml) MVA-CMDR IM by needle injection at weeks 24 and 36 in the same arm as HIVIS DNA. They will also receive 0.5 ml Cervarix at the time of the first MVACMDR injection in the opposite arm from the MVA injection at week 24.
Cervarix
Cervarix by IM needle injection at weeks 0, 4 and 24.
Stellenbosch University, Tygerberg Hills
Collaborators (1)
Bambino Gesù Hospital and Research Institute
OTHER
PENTA Foundation
NETWORK
Johns Hopkins University
OTHER
University of Miami
OTHER
Leidos Biomedical Research, Inc.
INDUSTRY
Case Western Reserve University
OTHER
Karolinska Institutet
OTHER
Walter Reed Army Institute of Research (WRAIR)
FED
Armed Forces Research Institute of Medical Sciences, Thailand
OTHER_GOV
University of Padova
OTHER
Chulalongkorn University
OTHER
Henry M. Jackson Foundation for the Advancement of Military Medicine
OTHER